Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH

References

• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330.
   PubMed Web of Science ®Google Scholar
• Jumpertz R, Le DS, Turnbaugh PJ, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011;94(1):58–65. doi:10.3945/ajcn.110.010132
   PubMed Web of Science ®Google Scholar
• Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci. 2004;101(44):15718–15723. doi:10.1073/pnas.0407076101
   PubMed Web of Science ®Google Scholar
• Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011;54(1):133–144. doi:10.1002/hep.24341
   PubMed Web of Science ®Google Scholar
• Rabot S, Membrez M, Bruneau A, et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 2010;24(12):4948–4959.
   PubMed Web of Science ®Google Scholar
• Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–609.
   PubMed Web of Science ®Google Scholar
• Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–775. doi:10.1002/hep.28356
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019;11(2). doi:10.15252/emmm.201809302
   PubMed Web of Science ®Google Scholar
• Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007;17(10):1374. doi:10.1007/s11695-007-9243-7
   PubMed Web of Science ®Google Scholar
• De Minicis S, Rychlicki C, Agostinelli L, et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014;59(5):1738–1749. doi:10.1002/hep.26695
   PubMed Web of Science ®Google Scholar
• Armougom F, Henry M, Vialettes B, Raccah D, Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One. 2009;4(9):e7125. doi:10.1371/journal.pone.0007125
   PubMed Web of Science ®Google Scholar
• Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480–484. doi:10.1038/nature07540
   PubMed Web of Science ®Google Scholar
• Walters WA, Xu Z, Knight R. Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett. 2014;588(22):4223–4233. doi:10.1016/j.febslet.2014.09.039
   PubMed Web of Science ®Google Scholar
• Sze MA, Schloss PD. Looking for a signal in the noise: revisiting obesity and the microbiome. MBio. 2016;7(4). doi:10.1128/mBio.01018-16
   PubMedGoogle Scholar
• Tseng C-H, Wu C-Y. The gut microbiome in obesity. J Formos Med Assoc. 2019;118(Suppl):S3–S9. doi:10.1016/j.jfma.2018.07.009
   PubMedGoogle Scholar
• Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y. Role of bile acids in dysbiosis and treatment of nonalcoholic fatty liver disease. Mediators Inflamm. 2019;2019:7659509. doi:10.1155/2019/7659509
   PubMed Web of Science ®Google Scholar
• Sun L, Ma L, Ma Y, Zhang F, Zhao C, Nie Y. Insights into the role of gut microbiota in obesity: pathogenesis, mechanisms, and therapeutic perspectives. Protein Cell. 2018;9(5):397–403. doi:10.1007/s13238-018-0546-3
   PubMed Web of Science ®Google Scholar
• Soares J-B, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int. 2010;4(4):659–672. doi:10.1007/s12072-010-9219-x
   PubMed Web of Science ®Google Scholar
• Testro AG, Visvanathan K. Toll‐like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol. 2009;24(6):943–954. doi:10.1111/j.1440-1746.2009.05854.x
   PubMed Web of Science ®Google Scholar
• Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58(1):120–127. doi:10.1002/hep.26319
   PubMed Web of Science ®Google Scholar
• Plessis J, Korf H, J V P, Windmolders P, Vander I. Pro-inflammatory cytokines but not endotoxin-related parameters associate with disease severity in patients with NAFLD. Plos One. 2016;1–15. DOI:10.1371/journal.pone.0166048
   Google Scholar
• Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll‐like receptor 4 is involved in the development of fructose‐induced hepatic steatosis in mice. Hepatology. 2009;50(4):1094–1104. doi:10.1002/hep.23122
   PubMed Web of Science ®Google Scholar
• Møller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood. 2002;99(1):378–380. doi:10.1182/blood.V99.1.378
   PubMedGoogle Scholar
• Hintz KA, Rassias AJ, Wardwell K, et al. Endotoxin induces rapid metalloproteinase‐mediated shedding followed by up‐regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol. 2002;72(4):711–717.
   PubMedGoogle Scholar
• Andersen ES, Rødgaard-Hansen S, Moessner B, Christensen PB, Møller HJ, Weis N. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study. Eur J Clin Microbiol Infect Dis. 2014;33(1):117–122. doi:10.1007/s10096-013-1936-3
   PubMedGoogle Scholar
• Mueller JL, Feeney ER, Bch MB, et al. Circulating soluble CD163 is associated with steatohepatitis and advanced fibrosis in nonalcoholic fatty liver disease. Clini Transl Gastroenterol. 2015;6(10):e114. doi:10.1038/ctg.2015.36
   PubMedGoogle Scholar
• Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191. doi:10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. doi:10.1002/hep.20701
   PubMed Web of Science ®Google Scholar
• Brunt EM, Kleiner DE, Wilson LA, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD—clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49(3):809–820. doi:10.1002/hep.22724
   PubMedGoogle Scholar
• Chan YH. Biostatistics 102: quantitative data–parametric & non-parametric tests. Blood Press. 2003;140(24.08):0–79.
   Google Scholar
• Chan YH. Biostatistics 103: qualitative data-tests of independence. Singapore Med J. 2003;44(10):498–503.
   PubMedGoogle Scholar
• Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander‐Tetri BA. (CRN) NCRN. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810–820. doi:10.1002/hep.24127
   PubMed Web of Science ®Google Scholar
• Moestrup SK, Møller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann Med. 2004;36(5):347–354. doi:10.1080/07853890410033171
   PubMed Web of Science ®Google Scholar
• Møller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK. Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher’s disease. Eur J Haematol. 2004;72(2):135–139. doi:10.1046/j.0902-4441.2003.00193.x
   PubMedGoogle Scholar
• Weaver LK, Hintz-Goldstein KA, Pioli PA, et al. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol. 2006;80(1):26–35. doi:10.1189/jlb.1205756
   PubMed Web of Science ®Google Scholar
• Mueller JL, Feeney ER, Zheng H, et al. Circulating soluble CD163 is associated with steatohepatitis and advanced fibrosis in nonalcoholic fatty liver disease. Clin Transl Gastroenterol. 2015;6:e114. doi:10.1038/ctg.2015.36
   PubMed Web of Science ®Google Scholar
• Chawla A, Nguyen KD, Goh YPS. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011;11(11):738–749. doi:10.1038/nri3071
   PubMed Web of Science ®Google Scholar
• Tam CS, Clément K, Baur LA, Tordjman J. Obesity and low-grade inflammation: a paediatric perspective. Obes Rev. 2010;11(2):118–126. doi:10.1111/j.1467-789X.2009.00674.x
   PubMedGoogle Scholar
• Trøseid M, Nestvold TK, Rudi K, Thoresen H, Nielsen EW, Lappegård KT. Plasma lipopolysaccharide is closely associated with glycemic control and abdominal obesity: evidence from bariatric surgery. Diabetes Care. 2013;36(11):3627–3632. doi:10.2337/dc13-0451
   PubMed Web of Science ®Google Scholar
• Kallio KAE, Hätönen KA, Lehto M, Salomaa V, Männistö S, Pussinen PJ. Endotoxemia, nutrition, and cardiometabolic disorders. Acta Diabetol. 2015;52(2):395–404. doi:10.1007/s00592-014-0662-3
   PubMedGoogle Scholar
• Basu S, Haghiac M, Surace P, et al. Pregravid obesity associates with increased maternal endotoxemia and metabolic inflammation. Obesity (Silver Spring). 2011;19(3):476–482. doi:10.1038/oby.2010.215
   PubMed Web of Science ®Google Scholar
• Frisard MI, McMillan RP, Marchand J, et al. Toll-like receptor 4 modulates skeletal muscle substrate metabolism. Am J Physiol Endocrinol Metab. 2010;298(5):E988–98. doi:10.1152/ajpendo.00307.2009
   PubMedGoogle Scholar
• Delzenne NM, Neyrinck AM, Cani PD. Modulation of the gut microbiota by nutrients with prebiotic properties: consequences for host health in the context of obesity and metabolic syndrome. Microb Cell Fact. 2011;10(Suppl 1):S10. doi:10.1186/1475-2859-10-S1-S10
   PubMedGoogle Scholar
• Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–1772. doi:10.2337/db06-1491
   PubMed Web of Science ®Google Scholar
• Du Plessis J, Korf H, van Pelt J, et al. Pro-inflammatory cytokines but not endotoxin-related parameters associate with disease severity in patients with NAFLD. PLoS One. 2016;11(12):e0166048. doi:10.1371/journal.pone.0166048
   PubMed Web of Science ®Google Scholar
• Santen RJ, Kagan R, Altomare CJ, Komm B, Mirkin S, Taylor HS. Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women. J Clin Endocrinol Metab. 2014;99(3):733–747. doi:10.1210/jc.2013-3680
   PubMedGoogle Scholar
• Parkner T, Sørensen LP, Nielsen AR, et al. Soluble CD163: a biomarker linking macrophages and insulin resistance. Diabetologia. 2012;55(6):1856–1862. doi:10.1007/s00125-012-2533-1
   PubMedGoogle Scholar
• Fjeldborg K, Christiansen T, Bennetzen MJ, Møller H, Pedersen SB, Richelsen B. The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss. Obesity. 2013;21(12):2437–2443. doi:10.1002/oby.20376
   PubMedGoogle Scholar
• Kazankov K, Møller HJ, Lange A, et al. The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children. Pediatr Obes. 2015;10(3):226–233. doi:10.1111/ijpo.252
   PubMed Web of Science ®Google Scholar
• De Vito R, Alisi A, Masotti A, et al. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int J Mol Med. 2012;30(1):49–56. doi:10.3892/ijmm.2012.965
   PubMedGoogle Scholar
• Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol. 2009;51(1):212–223. doi:10.1016/j.jhep.2009.03.008
   PubMed Web of Science ®Google Scholar
• Park J-W, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol. 2007;22(4):491–497. doi:10.1111/j.1440-1746.2006.04758.x
   PubMed Web of Science ®Google Scholar
• Fotiadu A, Gagalis A, Akriviadis E, et al. Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease. Pathol Int. 2010;60(2):87–92. doi:10.1111/j.1440-1827.2009.02489.x
   PubMedGoogle Scholar
• Kazankov K, Barrera F, Møller HJ, et al. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver Int. 2016;36(10):1549–1557. doi:10.1111/liv.13150
   PubMed Web of Science ®Google Scholar
• Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091–1103.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Ichimura M, Tsuneyama K, et al. Fructo-oligosaccharides and intestinal barrier function in a methionine–choline-deficient mouse model of nonalcoholic steatohepatitis. PLoS One. 2017;12(6):e0175406. doi:10.1371/journal.pone.0175406
   PubMed Web of Science ®Google Scholar
• Pachikian BD, Essaghir A, Demoulin J, et al. Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways. Mol Nutr Food Res. 2013;57(2):347–359. doi:10.1002/mnfr.201200364
   PubMedGoogle Scholar
• Dewulf EM, Cani PD, Claus SP, et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut. 2013;62(8):1112–1121. doi:10.1136/gutjnl-2012-303304
   PubMed Web of Science ®Google Scholar
• Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99(3):535–542.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Vacante M, Antic T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57(2):545–553. doi:10.1007/s10620-011-1887-4
   PubMed Web of Science ®Google Scholar
• Mofidi F, Poustchi H, Yari Z, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117(5):662–668. doi:10.1017/S0007114517000204
   PubMed Web of Science ®Google Scholar
• Asgharian A, Askari G, Esmailzade A, Feizi A, Mohammadi V. The effect of symbiotic supplementation on liver enzymes, C-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: a clinical trial. Int J Prev Med. 2016;7.
   PubMedGoogle Scholar
• Zhong L-J, Xie Z-S, Yang H, Li P, Xu X-J. Moutan Cortex and Paeoniae Radix Rubra reverse high-fat-diet-induced metabolic disorder and restore gut microbiota homeostasis. Chin J Nat Med. 2017;15(3):210–219. doi:10.1016/S1875-5364(17)30037-7
   PubMedGoogle Scholar
• Xu J, Chen H-B, Li S-L. Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota. Med Res Rev. 2017;37(5):1140–1185. doi:10.1002/med.21431
   PubMed Web of Science ®Google Scholar
• Ma J, Zhou Q, Li H. Gut microbiota and nonalcoholic fatty liver disease: insights on mechanisms and therapy. Nutrients. 2017;9(10):1124. doi:10.3390/nu9101124
   PubMed Web of Science ®Google Scholar